Medicon Valley Alliance and Pharmaron would like to welcome you to a Good Morning Meeting 11th of June 2025.
Imagine trying to discover and develop a medicine without knowledge of its metabolism and pharmacokinetic properties, or being able to contextualise drug behaviour across species using a range of computational, in vitro and in vivo approaches? Translational DMPK draws together biology, pharmacology and chemistry to model, predict and explain the relationship between drug concentration and effect in humans. Here, we will highlight the key capabilities offered by today’s DMPK scientists and how these capabilities are optimising the selection and development of modern medicines.
Date: Wednesday 11th of June 2025
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Welcome Barry Jones, Chief Scientist Global DMPK and Jens-Peter Muller, Business Development Director |
| 9:15 | Unlocking discovery and enabling clinical evaluation: Predicting human pharmacokinetics and dose Simon Taylor, Vice President, DMPK, Pharmaron |
| 9:40 | Enabling Drug Development: Considerations and Prediction of Drug-Drug Interactions Katherine Fenner, in vitro DMPK Laboratory Head, Pharmaron |
| 10:05 | From the identification of metabolic hotspots to hot molecule metabolism: current state and future of drug biotransformation studies Scott Summerfield, Senior Director Pharmaceutical Metabolism |
| 10:30 | Questions & Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Simon Taylor, Vice President, DMPK at Pharmaron
Simon Taylor is Vice President of Drug Discovery DMPK and is based in Hoddesdon, UK. With over 27 years industry experience he is responsible for DMPK/ADME and PKPD strategy, including human extrapolation and PBPK modelling and simulation, for Pharmaron’s integrated drug discovery projects from early discovery through to IND submission. Prior to Pharmaron, Simon worked at GSK for 20 years leading DMPK and Quantitative Pharmacology teams and projects from the Hit Identification stage through to the clinic. He has worked across respiratory, inflammation, oncology and cardiovascular therapy areas with drugs of varying routes of administration. |
 |
Katherine Fenner, in vitro DMPK Laboratory Head, at Pharmaron
Katherine Fenner is responsible for Pharmaron’s in vitro DMPK provision in UK & Europe. Katherine has over 30 years experience in DMPK, working previously in several roles, across both discovery and development DMPK for Pfizer and then AstraZeneca, where she directed an international in vitro ADME (absorption, distribution, metabolism & excretion) group. Katherine has published many peer reviewed publications, including several on drug-drug interactions, recently publishing a Pharm IQ paper, focused on in vitro transporter assessment and implications for Drug Development. |
 |
Scott Summerfield, Senior Director Pharmaceutical Metabolism at Pharmaron Scott is head of Metabolism leading clinical and nonclinical radiolabelled ADME (Pharma and Environmental), in vivo support, imaging, along with Discovery/Development and bioanalysis metabolite-ID. Scott joined Pharmaron in 2022 having worked in Pharma for over 20 years supporting small and large molecule DMPK projects (Discovery and Development). He holds a PhD and post-doc in protein MS and has published extensively in the areas of bioanalysis and permeation of drugs across the blood-brain barrier. |
| Organized by | In collaboration with |
 |
 |